Oxford Nanopore CEO lays out a more focused, partner-led push toward its 2030 targets, at Jefferies London
Oxford Nanopore chief executive Francis Van Parys told the Jefferies Global Healthcare Conference in London the company will own research and biopharma workflows, partner in the clinic, and sees scope for a $1 billion-plus revenue business over time, beyond its 2030 target of more than $700 million.
